![Freddy Radtke](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Rajwinder Lehal | M | 48 |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | 10 años |
Richard Peck | M | 73 |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | 10 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Michael Bauer | M | 58 |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | - |
Dirk Weber | M | 54 |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suiza | 4 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Freddy Radtke
- Red Personal